Other Events ·
Mira reports positive preclinical results for optimized SKNY-1 oral formulation targeting obesity and addiction
MIRAMira Pharmaceuticals, Inc.
MIRA Pharmaceuticals, Inc. announced on July 6, 2026, positive preclinical study results for the optimized oral formulation of SKNY-1, an oral drug candidate for obesity and addiction-related disorders. The studies demonstrated favorable oral bioavailability, systemic exposure, and robust brain penetration. MIRA Pharmaceuticals, Inc. is a biopharmaceutical company developing drug candidates for obesity and addiction-related disorders.